Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Advanced Solid Tumor 12Solid Tumor 5Nasopharyngeal Carcinoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 3Melanoma 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Sarcoma 2Recurrence 2Neoplasms 2Locally Advanced or Metastatic Solid Tumors 2Liposarcoma 2Advanced Solid Tumors 2Advanced Lung Cancer 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor, Adult 1Solid Cancer 1Small Cell Lung Carcinoma 1Pyloric Stenosis, Hypertrophic 1Pancreatic Neoplasms 1Pancreatic Cancer Metastatic 1PD-1 1Ovarian Neoplasms 1Meningeal Carcinomatosis 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Leiomyosarcoma 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × toripalimab × Clear all
NCT05615974 2024-12-19

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

LaNova Medicines Limited

Phase 1/2 Recruiting
139 enrolled
Tumor-Agnostic

Neoplasms

NCT06612632 2024-09-25

Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Recruiting
100 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡